These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
517 related articles for article (PubMed ID: 32648591)
1. The role of the CD39-CD73-adenosine pathway in liver disease. Wang S; Gao S; Zhou D; Qian X; Luan J; Lv X J Cell Physiol; 2021 Feb; 236(2):851-862. PubMed ID: 32648591 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical and functional analysis of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and ecto-5'-nucleotidase (CD73) in pig aortic valves. Kaniewska E; Sielicka A; Sarathchandra P; Pelikant-Małecka I; Olkowicz M; Słomińska EM; Chester AH; Yacoub MH; Smoleński RT Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):305-12. PubMed ID: 24940684 [TBL] [Abstract][Full Text] [Related]
3. CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression. Bono MR; Fernández D; Flores-Santibáñez F; Rosemblatt M; Sauma D FEBS Lett; 2015 Nov; 589(22):3454-60. PubMed ID: 26226423 [TBL] [Abstract][Full Text] [Related]
6. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice. Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240 [TBL] [Abstract][Full Text] [Related]
7. The adenosine generating enzymes CD39/CD73 control microglial processes ramification in the mouse brain. Matyash M; Zabiegalov O; Wendt S; Matyash V; Kettenmann H PLoS One; 2017; 12(4):e0175012. PubMed ID: 28376099 [TBL] [Abstract][Full Text] [Related]
8. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. Reutershan J; Vollmer I; Stark S; Wagner R; Ngamsri KC; Eltzschig HK FASEB J; 2009 Feb; 23(2):473-82. PubMed ID: 18838482 [TBL] [Abstract][Full Text] [Related]
9. CD73 controls ocular adenosine levels and protects retina from light-induced phototoxicity. Losenkova K; Takeda A; Ragauskas S; Cerrada-Gimenez M; Vähätupa M; Kaja S; Paul ML; Schmies CC; Rolshoven G; Müller CE; Sandholm J; Jalkanen S; Kalesnykas G; Yegutkin GG Cell Mol Life Sci; 2022 Feb; 79(3):152. PubMed ID: 35212809 [TBL] [Abstract][Full Text] [Related]
10. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade. Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420 [TBL] [Abstract][Full Text] [Related]
11. Extracellular generation of adenosine by the ectonucleotidases CD39 and CD73 promotes dermal fibrosis. Fernández P; Perez-Aso M; Smith G; Wilder T; Trzaska S; Chiriboga L; Franks A; Robson SC; Cronstein BN; Chan ESL Am J Pathol; 2013 Dec; 183(6):1740-1746. PubMed ID: 24266925 [TBL] [Abstract][Full Text] [Related]
12. Regulation of the T Cell Response by CD39. Takenaka MC; Robson S; Quintana FJ Trends Immunol; 2016 Jul; 37(7):427-439. PubMed ID: 27236363 [TBL] [Abstract][Full Text] [Related]
13. CD39 and CD73 in the aortic valve-biochemical and immunohistochemical analysis in valve cell populations and its changes in valve mineralization. Kaniewska-Bednarczuk E; Kutryb-Zajac B; Sarathchandra P; Pelikant-Malecka I; Sielicka A; Piotrowska I; Slominska EM; Chester AH; Yacoub MH; Smolenski RT Cardiovasc Pathol; 2018; 36():53-63. PubMed ID: 30056298 [TBL] [Abstract][Full Text] [Related]
14. Resident cardiac immune cells and expression of the ectonucleotidase enzymes CD39 and CD73 after ischemic injury. Bönner F; Borg N; Burghoff S; Schrader J PLoS One; 2012; 7(4):e34730. PubMed ID: 22514659 [TBL] [Abstract][Full Text] [Related]
15. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125 [TBL] [Abstract][Full Text] [Related]
16. Potential role of the CD39-CD73 ATP-adenosine pathway in platelet mediated dissemination of circulating tumour cells. Ward MP; O'Toole SA; O'Leary JJ Br J Cancer; 2024 Sep; 131(5):781-782. PubMed ID: 39128932 [No Abstract] [Full Text] [Related]
17. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease. Geraghty NJ; Watson D; Sluyter R Immunol Cell Biol; 2019 Jul; 97(6):597-610. PubMed ID: 30957314 [TBL] [Abstract][Full Text] [Related]
18. Coexpression of ecto-5'-nucleotidase/CD73 with specific NTPDases differentially regulates adenosine formation in the rat liver. Fausther M; Lecka J; Soliman E; Kauffenstein G; Pelletier J; Sheung N; Dranoff JA; Sévigny J Am J Physiol Gastrointest Liver Physiol; 2012 Feb; 302(4):G447-59. PubMed ID: 22135310 [TBL] [Abstract][Full Text] [Related]
19. Enzymes of the purinergic signaling system exhibit diverse effects on the degeneration of valvular interstitial cells in a 3-D microenvironment. Weber A; Barth M; Selig JI; Raschke S; Dakaras K; Hof A; Hesse J; Schrader J; Lichtenberg A; Akhyari P FASEB J; 2018 Aug; 32(8):4356-4369. PubMed ID: 29558203 [TBL] [Abstract][Full Text] [Related]
20. Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways. Giatromanolaki A; Kouroupi M; Pouliliou S; Mitrakas A; Hasan F; Pappa A; Koukourakis MI Life Sci; 2020 Oct; 259():118389. PubMed ID: 32898522 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]